Skip to content

The effect of remimazolam tosylate on the postoperative recovery quality of adult patients with obstructive sleep apnea syndrome after general anesthesia

The effect of remimazolam tosylate on the postoperative recovery quality of adult patients with obstructive sleep apnea syndrome after general anesthesia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128747
Enrollment
Unknown
Registered
2026-07-24
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea Syndrome,OSAS

Interventions

Remimazolam Group 2:Continuous intraoperative infusion of remimazolam at 0.4 mg/kg/h
Sodium Chloride Solution Group:Sodium Chloride Solution
Remimazolam Group 1:Continuous intraoperative infusion of remimazolam at 0.2 mg/kg/h

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Age 18 to 65. 2.American Society of Anesthesiologists (ASA) physical status I–III. 3.OSAS patients who are scheduled to undergo UPPP under general anesthesia.

Exclusion criteria

Exclusion criteria: 1.Those who are allergic to the drugs used in the research protocol. 2.Recently, there has been a history of fever and infection. 3.Due to cognitive, language, visual or hearing impairments or having mental illnesses that prevent one from cooperating. 4.Patients who have received systematic psychological treatment within the past three months or are currently taking anti-anxiety or anti-depression medications. 5.History of steroid or non-steroid anti-inflammatory drug use in the past one month. 6.Those with a history of severe respiratory or cardiovascular diseases or those with severely impaired liver and kidney functions. 7.Patients with myasthenia gravis. 8.Refusal to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
QoR-15 score;

Secondary

MeasureTime frame
QoR-15 score;Hospital Anxiety and Depression Scale (HADS) score;The total dosage of remifentanil, propofol and remifentanil used during the operation;MMSE(mini-mental state examination)score;Anesthesia duration;The rates of various adverse events;The incidence of delirium (assessed using the 3D-CAM scale);Satisfaction of doctors, patients or their families;Medication situation:The usage of vasoactive drugs during and after the operation, the situation of postoperative rescue analgesia and antiemesis, and the use of muscle relaxant antagonists;Numerical Rating Scale(NRS) score;Vital signs:Heart rate, non-invasive systolic blood pressure, non-invasive diastolic blood pressure, non-invasive mean arterial pressure, blood oxygen saturation, depth of anesthesia;

Countries

China

Contacts

Public ContactJingjing Yuan

The First Affiliated Hospital of Zhengzhou University

82513566@qq.com+86 371 6691 3144

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026